Screener
Syndax Pharmaceuticals SNDX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash provided by investing activities | 38,390 | 94,142 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from Employee Stock Purchase Plan | 458 | 545 |
| Proceeds from stock option exercises | 7,460 | 385 |
| Net cash provided by financing activities | 7,918 | 930 |
| NET DECREASE CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (4,037) | (90) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH—beginning of period | 135,032 | 154,300 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH —end of period | $130,995 | $154,210 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's financing cash flow?
- Syndax Pharmaceuticals (SNDX) reported financing cash flow of $7.92M in Q1 2026.
- How has Syndax Pharmaceuticals's financing cash flow changed year-over-year?
- Syndax Pharmaceuticals's financing cash flow increased by 751.4% year-over-year, from $930K to $7.92M.
- What is the long-term trend for Syndax Pharmaceuticals's financing cash flow?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's financing cash flow has grown at a -41.7% compound annual growth rate (CAGR), from $118.46M to $13.68M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Syndax Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude